---
category: news
title: "Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADRÂ® artificial intelligence (\"A.I.\") platform"
publishedDateTime: 2020-12-17T12:00:00Z
originalUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
webUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
type: article
quality: 15
heat: 15
published: false

provider:
  name: PR Newswire
  domain: prnewswire.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg?p=facebook"
    width: 939
    height: 491
    isCached: true

secured: "1RT97CcbAhpM0CARMYqiQjRUmVhEm27gxySY6j+8FAiGJPH4Lc0IwjI9CMWVBfX7X1Xjad3+QwAxNLmLaAJ3RZAi50duQMcE+Q/paZqXKjIRhzT0L//2eheG1qgq65uh/Uzc3ln4aoexBzA/HZpIhHLITYUMmbrqbr9Qcwclx5poE1f8X8/XQuAD8Tr9zU6em3v/t4QB3Y/9ljGWTwRJkoC5pfSuTAUWoqkwpErefLLnTZz9LpiUFcV9zxaLlqs3MYL7i9MCUidMV59rQgDMg1V5r5/SLcCJeF1ndqSCQOkCs0LHoGQS1HqqqYlmSZ9S+CHdZVc21/0DL5AuGmNiIWgRwRXWNd8rh/92sM5TKcI=;IH1edFDLS0gghrSadcn2Ow=="
---

